Author(s)

Siwei Luo ¹

Affiliation(s)

¹ Jiangxi University of Science and Technology, Ganzhou, Jiangxi, China

Corresponding Author

Siwei Luo

ABSTRACT

In order to further improve the people's quality of life, so that the broad masses of people at a lower price to enjoy higher quality drug services, the government organized the national centralized procurement of drugs. With the implementation of the national centralized drug procurement system, the profits of Chinese pharmaceutical enterprises have been greatly affected, and pharmaceutical enterprises are facing unprecedented challenges. This paper takes HB pharmaceutical enterprises as the research subject and explores the transformation and development path of pharmaceutical enterprises through financial analysis and analysis of advantages and disadvantages.

KEYWORDS

Drug Collection, Transformation and Development, Path Study

CITE THIS PAPER

Siwei Luo, Exploration and Research on the Development Status and Transformation Development Path of Hb Pharmaceutical Enterprises under Drug Collection. Accounting and Corporate Management (2023) Vol. 5: 5-12. DOI: http://dx.doi.org/10.23977/acccm.2023.050302.

REFERENCES

[1] Gu Yu. Research on Strategic Transformation of Pharmaceutical Enterprises [D]. Henan University of Economics and Law,2022.
[2] Wu Jing, Jiao Jing. Analysis on the causes of financial risk of North China Pharmaceutical Company [J]. Investment and Cooperation, 2021(12):34-35. (in Chinese)
[3] Zhao Jianlin, Zhu Yun. The truth of "cut off supply" in Huabei Pharmaceutical Collection [J]. Business School, 2021(10):104-107.
[4] Zhang Xiaopeng. Enterprise Development strategy Transformation and Path Choice [J]. Modern Economic Information, 2019(18):116.
[5] Xiao Wei. Research on the transformation and development path of Small and medium-sized pharmaceutical enterprises under the new medical reform situation [D]. Southeast University,2018.
[6] Domínguez Asenjo Bárbara, Gutiérrez Corbo Camino, Álvarez Bardón María, Pérez Pertejo Yolanda, Balaña Fouce Rafael & Reguera Rosa M.(2021).Ex Vivo Phenotypic Screening of Two Small Repurposing Drug Collections Identifies Nifuratel as a Potential New Treatment against Visceral and Cutaneous Leishmaniasis. ACS infectious diseases. doi:10.1021/ACSINFECDIS.1C00139.
[7] Tarpley Michael, Oladapo Helen O., Strepay Dillon, Caligan Thomas B.,Chdid Lhoucine, Shehata Hassan... & Williams Kevin P..(2021) Identification of harmine and β-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies. European Journal of Pharmaceutical Sciences (prepublish). doi:10.1016/J.EJPS.2021.105821.
[8] Onyebuchi Okpolosa Matthew, Lebari Konee Innocent, Adams M. B.,Abor J., Ahmed A. A., Akintoye I. R.... & Wong K. P. (2022). Leverage and financial performance of listed pharmaceutical enterprises in Nigeria. Asian Journal Of Multidimensional Research(7). doi:10.5958/2278-4853.2022.00171.9.
[9] Zhuang Zhipeng, Luo Jinglin & Xu Mingxin. (2021). Example of VOCs waste gas treatment in a pharmaceutical enterprise. IOP Conference Series: Earth and Environmental Science(1). doi:10.1088/1755-1315/831/1/012069.
[10] Rita Sahaidak Nikitiuk, Karyna Holybtsova, Nataliya Demchenko & Mariya Zarichkova.(2020).Theoretical and applied aspects of adaptive management of manufacturing pharmaceutical enterprises of Ukraine. ScienceRise: Pharmaceutical Science(6). doi:10.15587/2519-4852.2020.222219.
[11] Yumei Luo, Luo Yumei, Wang Guiping & Li Yuwei. (2020).Research on the Legitimacy Acquisition of Reverse Logistics for Pharmaceutical Enterprises. IOP Conference Series: Earth and Environmental Science(1). doi:10.1088/1755-1315/615/1/012044.
[12] Yu Jingting. (2021). Strategy and Development Path of pharmaceutical marketing. Modern Marketing (Academy Edition)(05), 72-73. doi:10.19932/j.cnki.22-1256/F.2021.05.072.
[13] Zhang Rui & Shi Zhiwei. (2021). Research on Innovative Development Path of Suzhou Pharmaceutical Industry Cluster. Modern Management Science (02), 51-57.
[14] Yang Chenxi. (2019). Research on innovation and development path of Chinese small and medium-sized pharmaceutical enterprises -- Based on SWOT analysis of Beijing Jiurong Pharmaceutical Co., LTD. Modern business (31), 79-80. The doi: 10.14097 / j.carol carroll nki. 5392/2019.31.030.
[15] CAI Y. (2018). Exploring the transformation and development path of pharmaceutical circulation enterprises from the perspective of industrial supply chain. Research on Modern State-owned Enterprises (10), 71-72.

Sponsors, Associates, and Links

---

• Information Systems and Economics
  
  
• Accounting, Auditing and Finance
  
  
• Industrial Engineering and Innovation Management
  
  
• Tourism Management and Technology Economy
  
  
• Journal of Computational and Financial Econometrics
  
  
• Financial Engineering and Risk Management
  
  
• Social Security and Administration Management
  
  
• Population, Resources & Environmental Economics
  
  
• Statistics & Quantitative Economics
  
  
• Agricultural & Forestry Economics and Management
  
  
• Social Medicine and Health Management
  
  
• Land Resource Management
  
  
• Information, Library and Archival Science
  
  
• Journal of Human Resource Development
  
  
• Manufacturing and Service Operations Management
  
  
• Operational Research and Cybernetics